Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03897738
Other study ID # AmberenSmartB-2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 30, 2019
Est. completion date February 18, 2020

Study information

Verified date February 2020
Source I.M. Sechenov First Moscow State Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate effectiveness and safety of combined use of dietary supplements Amberen and Smart B in women with a typical (without complications) form of climacteric syndrome, with mild to moderate symptoms in perimenopause.


Description:

1. To evaluate effectiveness of combined use of dietary supplements Amberen and Smart B in women vasomotor, psychosomatic, psychological and other climacteric symptoms in perimenopause.

2. To evaluate safety of combined use of dietary supplements Amberen and Smart B in women with vasomotor, psychosomatic, psychological and other climacteric symptoms in perimenopause.

3. To develop recommendations for combined use of dietary supplements Amberen and Smart B for women with vasomotor, psychosomatic, psychological and other climacteric symptoms in perimenopause.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date February 18, 2020
Est. primary completion date February 18, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A to 50 Years
Eligibility Inclusion Criteria:

- Female subjects, 50 years of age or younger;

- Subjects in the second phase of menopausal transition as per STRAW 10+ i.e. interval of amenorrhea 60 days or more (with regular menstrual cycle during earlier reproductive stages).

- Subjects with diagnosis of mild to moderate climacteric syndrome;

- Recent (up to 12 months prior to study enrollment) breast exam results, including mammogram, that rule out malignancies;

- Recent (up to 3 years prior to study enrollment) cytological screening that rules out vaginal cervix malignancies.

- Ability to read and understand informed consent form for the study's participation;

- Ability to adhere to the conditions of the study.

Exclusion Criteria:

- • Postmenopause, including surgical menopause.

- Presence of hormone-dependent cancers;

- Presence of other cancers, not in full remission with no recurrence for 5 years or more;

- Planned hospitalization in the next 6 months;

- Presence of hormonally-active extragenital endocrine diseases (diabetes; diseases of thyroid, adrenal, pituitary) that require prolonged or life-long therapies

- Surgical interventions on sex organs or breasts, 1 year or less prior to the screening;

- Gynecological conditions that may require hormonal therapies or surgeries (uterine myoma, endometriosis, endometrial hyperplasia etc.);

- Currently undergoing or planning to utilize assisted reproductive technologies;

- Any abdominal surgeries within less than 3 months prior to the screening;

- HRT including MHRT or hormonal contraceptives - current or within less than 3 months prior to the screening;

- Psychiatric conditions;

- Patients taking any other dietary supplements that can affect climacteric syndrome within the last month before enrolling in the trial;

- High risk of non-compliance.

Study Design


Related Conditions & MeSH terms

  • Perimenopause, Climacteric Syndrome
  • Syndrome

Intervention

Dietary Supplement:
Amberen
Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
Smart B
Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
Placebo
Placebo capsules are identical to Amberen and Smart B capsules.

Locations

Country Name City State
Russian Federation Sechenov First Moscow Medical University Moscow

Sponsors (1)

Lead Sponsor Collaborator
I.M. Sechenov First Moscow State Medical University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary "Heart beating quickly and strongly" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 1 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Feeling tense or nervous" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 2 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Difficulty sleeping" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 3 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Increased Excitability" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 4 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Panic attacks" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 5 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Difficulty concentrating" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 6 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Feeling tired or lacking energy" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 7 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Loss of interest in most things" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 8 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Feeling of sadness or depression" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 9 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Crying spells" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 10 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Irritability" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 11 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Feeling dizzy or faint" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 12 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Pressure or tightness in head or body" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 13 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Parts of body feeling numb or tingling" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 14 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Headaches" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 15 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Muscle or joint pains" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 16 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Loss of feeling in hands or feet" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 17 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Breathing difficulties" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 18 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Hot flushes" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 19 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Night sweats" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 20 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 days and 180 days
Primary "Loss of interest in sex" symptom (Greene Climacteric Scale) Statistically significant change in designated symptom severity, compared between arms. This is question 21 of the Greene Climacteric Scale; the subjects rank degrees of bother of the symptom as 1 = "not at all"; 2 = "a little bit"; 3 = "quite a bit"; 4 = "extremely" 90 and 180 days
Primary Blood plasma estradiol levels, pg/ml Statistically significant changes in the levels, compared between arms 90 and 180 days
Secondary State-Trait Anxiety Inventory (State anxiety sub-scale) Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety. 90 and 180 days
Secondary State-Trait Anxiety Inventory (Trait anxiety sub-scale) Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety. 90 and 180 days
Secondary State-Trait Anxiety Inventory (Actual anxiety, combination of state and trait sub-scales ) Statistically significant change of the score in corresponding sub-scale. Scores range from 20 to 80, with higher scores correlating with greater anxiety. 90 and 180 days
Secondary Well-being sub-score (Russian well-being, activity and mood questionnaire) Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of well-being. 90 and 180 days
Secondary Activity sub-score (Russian well-being, activity and mood questionnaire) Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of one's activity. 90 and 180 days
Secondary Mood sub-score (Russian well-being, activity and mood questionnaire) Statistically significant change in designated symptom severity, compared between arms. The sub-scale score varies from 10 to 70 points, with the higher score corresponding to more positive self-evaluation of one's mood. 90 and 180 days
Secondary Anxiety sub-score (measured by Hospital Anxiety and Depression Scale) Statistically significant change in designated symptom severity, compared between arms. The scores range from 0 to 21.
0-7 = Normal 8-10 = Borderline abnormal 11-21 = Abnormal
90 and 180 days
Secondary Depression sub-score (measured by Hospital Anxiety and Depression Scale) Statistically significant change in designated symptom severity, compared between arms. The scores range from 0 to 21.
0-7 = Normal 8-10 = Borderline abnormal 11-21 = Abnormal
90 and 180 days